ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The US Food and Drug Administration has approved Brexafemme, an oral antifungal for vaginal yeast infections developed by the biotech firm Scynexis. The drug’s active compound, ibrexafungerp, is a glucan synthase inhibitor that is in a new class of drugs called triterpenoids. The compound, which Scynexis calls the first approved novel antifungal in more than 20 years, is effective against Candida species, including some drug-resistant strains.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter